COMPASS Pathways (CMPS)
(Delayed Data from NSDQ)
$8.11 USD
+0.17 (2.14%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $8.10 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CMPS 8.11 +0.17(2.14%)
Will CMPS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CMPS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CMPS
COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
CMPS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
Other News for CMPS
Psychedelic drug developers could benefit from NIH funding for chronic pain
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
Compass Pathways, Journey Clinical establish research collaboration
COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Here's What You Missed in Cannabis, Psychedelics This Week